JP2019503984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503984A5 JP2019503984A5 JP2018521955A JP2018521955A JP2019503984A5 JP 2019503984 A5 JP2019503984 A5 JP 2019503984A5 JP 2018521955 A JP2018521955 A JP 2018521955A JP 2018521955 A JP2018521955 A JP 2018521955A JP 2019503984 A5 JP2019503984 A5 JP 2019503984A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- dkk2
- subject
- antibody
- humanized anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 201000011510 cancer Diseases 0.000 claims description 43
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 claims description 30
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 16
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 14
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 14
- 201000002528 pancreatic cancer Diseases 0.000 claims description 14
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 14
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 12
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 12
- 230000003472 neutralizing effect Effects 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 9
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000002313 intestinal cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 6
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 101150108150 DKK2 gene Proteins 0.000 claims description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 2
- 101100223943 Homo sapiens DKK2 gene Proteins 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 230000005809 anti-tumor immunity Effects 0.000 claims description 2
- 229940022399 cancer vaccine Drugs 0.000 claims description 2
- 238000009566 cancer vaccine Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 229940032219 immunotherapy vaccine Drugs 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562247410P | 2015-10-28 | 2015-10-28 | |
| US62/247,410 | 2015-10-28 | ||
| PCT/US2016/057814 WO2017074774A1 (en) | 2015-10-28 | 2016-10-20 | Humanized anti-dkk2 antibody and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019503984A JP2019503984A (ja) | 2019-02-14 |
| JP2019503984A5 true JP2019503984A5 (OSRAM) | 2019-11-28 |
| JP6921067B2 JP6921067B2 (ja) | 2021-08-18 |
Family
ID=58630689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521955A Active JP6921067B2 (ja) | 2015-10-28 | 2016-10-20 | ヒト化抗Ｄｋｋ２抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11267875B2 (OSRAM) |
| EP (1) | EP3368567B1 (OSRAM) |
| JP (1) | JP6921067B2 (OSRAM) |
| KR (1) | KR20180085723A (OSRAM) |
| CN (1) | CN108463247B (OSRAM) |
| AU (1) | AU2016344459B2 (OSRAM) |
| CA (1) | CA3003252C (OSRAM) |
| DK (1) | DK3368567T3 (OSRAM) |
| IL (1) | IL258924A (OSRAM) |
| RU (1) | RU2018119317A (OSRAM) |
| WO (1) | WO2017074774A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018119317A (ru) | 2015-10-28 | 2019-12-04 | Йейл Юниверсити | Гуманизированное антитело к dkk2 и его применение |
| SG10202106830VA (en) | 2018-08-10 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
| AU2020216494A1 (en) | 2019-02-01 | 2021-08-12 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against MHC-bound human Dickkopf-1 peptides and uses thereof |
| EP3693063A1 (en) * | 2019-02-06 | 2020-08-12 | Diaccurate | Methods and compositions for treating cancer |
| WO2021003687A1 (en) * | 2019-07-10 | 2021-01-14 | Yale University | Compositions and methods of using a humanized anti-dkk2 antibody |
| TWI895351B (zh) * | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| JPH08500962A (ja) | 1992-02-06 | 1996-02-06 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 癌マーカー用生物合成結合蛋白質 |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6133232A (en) | 1996-06-20 | 2000-10-17 | The Regents Of The University Of California | Endoderm, cardiac and neural inducing factors |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| US7057017B2 (en) * | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| WO2003052082A2 (en) | 2001-12-18 | 2003-06-26 | Whitehead Institute For Biomedical Research | Fusion partner cells and uses thereof |
| US7595048B2 (en) * | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| WO2005042743A2 (en) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanization of antibodies |
| CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| KR100781753B1 (ko) * | 2006-05-24 | 2007-12-04 | 연세대학교 산학협력단 | Ｄｋｋ2를 포함하는 혈관신생을 촉진시키는 방법 |
| US8481688B2 (en) * | 2010-05-11 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-FGFR2 antibodies |
| CN103608037B (zh) | 2011-02-01 | 2016-04-13 | 香港大学 | 抗dkk1单克隆抗体用于治疗肝癌的用途 |
| CN105073133B (zh) | 2012-12-21 | 2021-04-20 | Aveo制药公司 | 抗gdf15抗体 |
| KR101508052B1 (ko) | 2013-05-20 | 2015-04-08 | 울산대학교 산학협력단 | 생물학적 활성을 가진 인간 Ｄｋｋ２ 재조합 단백질의 수용성 발현 및 정제방법 |
| CN106659912B (zh) | 2014-07-03 | 2021-11-30 | 耶鲁大学 | Dickkopf2(Dkk2)抑制作用抑制肿瘤形成 |
| WO2016196389A1 (en) * | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| RU2018119317A (ru) | 2015-10-28 | 2019-12-04 | Йейл Юниверсити | Гуманизированное антитело к dkk2 и его применение |
-
2016
- 2016-10-20 RU RU2018119317A patent/RU2018119317A/ru not_active Application Discontinuation
- 2016-10-20 CN CN201680075535.2A patent/CN108463247B/zh active Active
- 2016-10-20 CA CA3003252A patent/CA3003252C/en active Active
- 2016-10-20 DK DK16860530.1T patent/DK3368567T3/da active
- 2016-10-20 JP JP2018521955A patent/JP6921067B2/ja active Active
- 2016-10-20 WO PCT/US2016/057814 patent/WO2017074774A1/en not_active Ceased
- 2016-10-20 KR KR1020187013788A patent/KR20180085723A/ko not_active Ceased
- 2016-10-20 EP EP16860530.1A patent/EP3368567B1/en active Active
- 2016-10-20 AU AU2016344459A patent/AU2016344459B2/en active Active
- 2016-10-20 US US15/771,965 patent/US11267875B2/en active Active
-
2018
- 2018-04-25 IL IL258924A patent/IL258924A/en unknown
-
2022
- 2022-02-07 US US17/666,018 patent/US20220162294A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503984A5 (OSRAM) | ||
| Dhanyamraju et al. | Melanoma therapeutics: a literature review | |
| US20250177494A1 (en) | Methods of cytotoxic gene therapy to treat tumors | |
| Kamran et al. | Current state and future prospects of immunotherapy for glioma | |
| US20210299187A1 (en) | Cancer therapy | |
| CN107073099B (zh) | 用于治疗癌症的联合方法 | |
| JP7200093B2 (ja) | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 | |
| RU2018119317A (ru) | Гуманизированное антитело к dkk2 и его применение | |
| Almquist et al. | The role of immune checkpoint inhibitors in colorectal adenocarcinoma | |
| JP2017527533A5 (OSRAM) | ||
| JP6892443B2 (ja) | がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム | |
| IL255312B (en) | Therapeutic and diagnostic methods for cancer comprising a pd-l1 binding antagonist | |
| Alsina et al. | Immunotherapy of esophageal cancer: current status, many trials and innovative strategies | |
| Ostios-Garcia et al. | Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer | |
| Afolabi et al. | Synergistic tumor cytolysis by NK cells in combination with a pan-HDAC inhibitor, panobinostat | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| Misra et al. | Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective | |
| KR20210106531A (ko) | 암 치료를 위한 조성물 및 방법 | |
| Dovedi et al. | Emerging targeted therapies for bladder cancer: a disease waiting for a drug | |
| Li et al. | Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade | |
| Ramos et al. | The position of EGF deprivation in the management of advanced non-small cell lung cancer | |
| JP2021502344A (ja) | 腫瘍を処置する方法 | |
| WO2019094352A1 (en) | Inhibition of ctla-4 and/or pd-1 for regulation of t cells | |
| Sunami et al. | Immunotherapy for pancreatic cancer | |
| Lenzen et al. | Immu-01. Novel rna-targeting strategy for treating T cell-driven immunosuppression in human diffuse intrinsic pontine glioma |